About the Core
The ATC Human Stem Cell Core is currently undergoing reorganization and will soon be merging with the Human Neuronal Differentiation Core at the Jan and Dan Duncan Neurological Research Institute. This should provide more efficient utilization of resources (space, equipment and personnel) and elimination of some duplication of services currently provided by each core. The new Human Neuronal Differentiation and Stem Cell Core service list will offer the combined list of services developed by the two original cores and will operate under guidelines for BCM Institutional Advanced Technology Cores (ATC) in coordination with NRI/TCH procedures. The Director of the merged core is Aleksandar Bajic, Ph.D. and requests for services originally offered by Human Stem Cell Core can continue to be made on iLabs.
We provide intensive hands-on training on human pluripotent stem cell culture for Baylor College of Medicine, MD Anderson, and other Texas Medical Center investigators. View class information.
Human Stem Cell Services
The HSCC offers cost-effective solutions to generate and characterize novel human induced pluripotent stem (iPS) cells for in vitro disease modeling, employing “zero-footprint” technologies. View our services.
Information for Acknowledgement of Cores in Publications
Core Name: Human Stem Cell Core
Personnel: Aleksandar Bajic, Ph.D., Core Director; Hyekyung Park and Anel LaGrone, Research staff
Grants: NIH P30 CA125123 Shared Resource (PI: Osborne) and NIH S10 OD028591 (PI: Kim)
Cells and Quality Control Testing
The HSCC provides a reliable and well characterized source of undifferentiated human ES cells and iPS cells. See more information.
Major Products and Services
- Hands-on training classes and workshops
- Consultation on experimental design
- Human pluripotent stem cell (hPSC) culture services
- Generation of induced pluripotent stem (iPS) cell lines
- Stem cell line characterization (karyotyping and trilineage differentiation)
- Mycoplasma testing
- Customized genome editing of hPSCs using CRISPR/Cas9